Impetigo Medication: Topical Antimicrobials, Antibiotics, Other, Antihistamines, 2nd Generation, Antihistamines, 1st Generation (original) (raw)

Medication Summary

Topical antibiotics, systemic antibiotics, or a combination of both is effective therapy for impetigo. Empiric bacterial coverage is aimed at eradicating Staphylococcus aureus and group A beta-hemolytic streptococci (GABHS; also known as Streptococcus pyogenes). Antihistamines may be prescribed for symptomatic relief in patients with pruritus.

Mupirocin applied topically has been shown to be effective for localized impetigo, but resistance has emerged. Retapamulin is a newer option. [50, 65] Bacitracin is no longer recommended, as it is not as efficacious and causes frequent allergic skin reactions and occasional-to-rare anaphylaxis. [55]

The advantages of topical antibiotics include the following [55, 66] :

The disadvantages of topical antibiotics include the following [55] :

Systemic antibiotic treatment is indicated for widespread infections, complicated infections, or those associated with systemic manifestations. A cephalosporin, semisynthetic penicillin, or beta-lactam/beta-lactamase inhibitor combination is generally suitable for first-line therapy.

Methicillin-resistant Staphylococcus aureus (MRSA) should be suspected in cases of spontaneous abscess or cellulitis and in lesions that do not resolve with traditional antimicrobial therapy, in which case alternative antibiotics should be considered. These include trimethoprim-sulfamethoxazole, tetracycline, clindamycin, fluoroquinolones, and linezolid.

In areas with a high percentage of community-acquired MRSA, the empiric antibiotic choice should provide coverage for this possibility.

eMedicine Logo

Topical Antimicrobials

Class Summary

Topical antibiotic treatment with mupirocin is the treatment of choice for uncomplicated localized pyoderma, although S aureus resistance to mupirocin has been increasing.

Mupirocin (Bactroban, Centany)

Mupirocin is a naturally occurring antibiotic produced by fermentation of Pseudomonas fluorescens. The mechanism of action of mupirocin is via inhibition of bacterial protein synthesis.

Retapamulin (Altabax)

Retapamulin is a topical antibiotic available as a 1% ointment. It is the first of a new antibiotic class called pleuromutilins. This agent inhibits protein synthesis by binding to the 50S subunit on the ribosome. It is indicated for impetigo caused by S aureus or Streptococcus pyogenes.

Ozenoxacin (Xepi)

Ozenoxacin, a quinolone antimicrobial drug, works by inhibiting the bacterial DNA replication enzymes, DNA gyrase A and topoisomerase IV. It has been shown to be bactericidal against S. aureus and S. pyogenes organisms.

eMedicine Logo

Antibiotics, Other

Class Summary

Systemic antibiotic treatment is indicated for widespread or complicated pyoderma.

Amoxicillin and clavulanate (Augmentin)

This oral antibiotic combines the broad-spectrum antibiotic amoxicillin with the beta-lactamase inhibitor clavulanate. Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanate inhibits beta-lactamase producing bacteria.

For children older than 3 months, dosing is based on the amoxicillin content. Because of different amoxicillin-clavulanate ratios in the 250-mg tab (250mg/125mg) versus the 250-mg chewable tab (250mg/62.5mg), do not use the 250-mg tab until the child weighs more than 40 kg.

Dicloxacillin

Dicloxacillin binds to one or more penicillin-binding proteins, which, in turn, inhibits synthesis of bacterial cell walls. It is indicated for treatment of infections caused by penicillinase-producing staphylococci. This agent may be used to initiate therapy when staphylococcal infection is suspected.

Erythromycin (E.E.S., Ery-Tab, Erythrocin)

Erythromycin inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. It is used for the treatment of staphylococcal and streptococcal infections. However, macrolide resistance in the United States has been increasing. Erythromycin is used only when other options are unavailable or contraindicated.

In children, the patient's age and weight and the severity of the infection determine the proper dosage. When twice-daily dosing is desired, a half-total daily dose may be taken every 12 hours. For more severe infections, double the dose.

Clindamycin (Cleocin)

Clindamycin is a lincosamide used for the treatment of serious skin and soft tissue staphylococcal infections. It is also effective against aerobic and anaerobic streptococci (except enterococci). It inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest.

Trimethoprim-sulfamethoxazole (Bactrim DS, Septra DS)

Trimethoprim-sulfamethoxazole selectively inhibits bacterial dihydrofolate reductase. It has good susceptibility against community-acquired MRSA but is not effective against S pyogenes.

Levofloxacin (Levaquin)

This agent inhibits DNA gyrase and topoisomerase IV, resulting in bactericidal activity. It is used as an alternative agent for MRSA infection.

Ciprofloxacin (Cipro)

Ciprofloxacin inhibits DNA gyrase and topoisomerase IV, resulting in bactericidal activity. Use this agent as an alternative for MRSA infection.

Linezolid (Zyvox)

Linezolid binds to the 50S ribosomal subunit, interfering with protein synthesis. This agent is used for MRSA or complicated skin infections.

eMedicine Logo

Antihistamines, 2nd Generation

Class Summary

If pruritus is significant, antihistamines can be prescribed to possibly help minimize scratching. Avoidance of trauma to the skin may prevent or limit the spread of impetigo by autoinoculation. These agents selectively inhibit peripheral histamine H1 receptors to histamine.

Desloratadine (Clarinex)

Desloratadine is a long-acting tricyclic histamine antagonist that is selective for the H1 receptor. It relieves nasal congestion and systemic effects of seasonal allergy. It is the major metabolite of loratadine, which, after ingestion, is metabolized extensively to the active metabolite 3-hydroxydesloratadine.

Cetirizine (Zyrtec)

Cetirizine selectively inhibits histamine H1 receptor sites in blood vessels, the GI tract, and the respiratory tract, which, in turn, inhibits physiologic effects that histamine normally induces at H1 receptor sites. Once-daily dosing is convenient. Bedtime dosing may be useful if sedation is a problem.

Loratadine (Claritin, Alavert, Loradamed, Tavist ND)

Loratadine is nonsedating and selectively inhibits peripheral histamine H1 receptors.

eMedicine Logo

Antihistamines, 1st Generation

Class Summary

These agents selectively inhibit peripheral histamine H1 receptors to histamine.

Hydroxyzine (Vistaril)

Hydroxyzine antagonizes H1 receptors in the periphery. It may suppress histamine activity in the subcortical region of the CNS. It is often administered before sleep because of its sedating properties.

eMedicine Logo

  1. Moulin F, Quinet B, Raymond J, Gillet Y, Cohen R. [Managing children skin and soft tissue infections]. Arch Pediatr. 2008 Oct. 15 Suppl 2:S62-7. [QxMD MEDLINE Link].
  2. Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis. 2005 Jun. 11(6):928-30. [QxMD MEDLINE Link].
  3. Kuniyuki S, Nakano K, Maekawa N, Suzuki S. Topical antibiotic treatment of impetigo with tetracycline. J Dermatol. 2005 Oct. 32(10):788-92. [QxMD MEDLINE Link].
  4. Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. 2007 Mar 15. 75(6):859-64. [QxMD MEDLINE Link].
  5. Hirschmann JV. Impetigo: etiology and therapy. Curr Clin Top Infect Dis. 2002. 22:42-51. [QxMD MEDLINE Link].
  6. Geria AN, Schuartz RA. Impetigo Update: New Challenges in the Era of Methicillin Resistance. Cutis. 2010. 85(2):65-70.
  7. Treating impetigo in primary care. Drug Ther Bull. 2007 Jan. 45(1):2-4. [QxMD MEDLINE Link].
  8. Broccardo CJ, Mahaffey S, Schwarz J, et al. Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization. J Allergy Clin Immunol. 2011 Jan. 127(1):186-93, 193.e1-11. [QxMD MEDLINE Link]. [Full Text].
  9. Yamasaki O, Tristan A, Yamaguchi T, et al. Distribution of the exfoliative toxin D gene in clinical Staphylococcus aureus isolates in France. Clin Microbiol Infect. 2006 Jun. 12(6):585-8. [QxMD MEDLINE Link].
  10. Daskalaki M, Rojo P, Marin-Ferrer M, Barrios M, Otero JR, Chaves F. Panton-Valentine leukocidin-positive Staphylococcus aureus skin and soft tissue infections among children in an emergency department in Madrid, Spain. Clin Microbiol Infect. 2010 Jan. 16(1):74-7. [QxMD MEDLINE Link].
  11. Geng W, Yang Y, Wu D, et al. Molecular characteristics of community-acquired, methicillin-resistant Staphylococcus aureus isolated from Chinese children. FEMS Immunol Med Microbiol. 2010 Apr. 58(3):356-62. [QxMD MEDLINE Link].
  12. Liu Y, Kong F, Zhang X, Brown M, Ma L, Yang Y. Antimicrobial susceptibility of Staphylococcus aureus isolated from children with impetigo in China from 2003 to 2007 shows community-associated methicillin-resistant Staphylococcus aureus to be uncommon and heterogeneous. Br J Dermatol. 2009 Dec. 161(6):1347-50. [QxMD MEDLINE Link].
  13. Loffeld A, Davies P, Lewis A, Moss C. Seasonal occurrence of impetigo: a retrospective 8-year review (1996-2003). Clin Exp Dermatol. 2005 Sep. 30(5):512-4. [QxMD MEDLINE Link].
  14. Koning S, Verhagen AP, van Suijlekom-Smit LW, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2004. CD003261. [QxMD MEDLINE Link].
  15. Razmjou RG, Willemsen SP, Koning S, et al. Determinants of regional differences in the incidence of impetigo. Environ Res. 2009 Jul. 109(5):590-3. [QxMD MEDLINE Link].
  16. Spurling G, Askew D, King D, Mitchell GK. Bacterial skin infections--an observational study. Aust Fam Physician. 2009 Jul. 38(7):547-51. [QxMD MEDLINE Link].
  17. Romani L, Steer AC, Whitfeld MJ, Kaldor JM. Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect Dis. 2015 Aug. 15 (8):960-7. [QxMD MEDLINE Link].
  18. Tasani M, Tong SY, Andrews RM, Holt DC, Currie BJ, Carapetis JR, et al. The Importance of Scabies Coinfection in the Treatment Considerations for Impetigo. Pediatr Infect Dis J. 2016 Apr. 35 (4):374-8. [QxMD MEDLINE Link].
  19. Patrizi A, Raone B, Savoia F, Ricci G, Neri I. Recurrent toxin-mediated perineal erythema: eleven pediatric cases. Arch Dermatol. 2008 Feb. 144(2):239-43. [QxMD MEDLINE Link].
  20. Bangert S, Levy M, Hebert AA. Bacterial resistance and impetigo treatment trends: a review. Pediatr Dermatol. 2012 May-Jun. 29(3):243-8. [QxMD MEDLINE Link].
  21. George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. 2003 Jun. 53(491):480-7. [QxMD MEDLINE Link]. [Full Text].
  22. Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, Morris AD, Butler CC, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012 Jan 18. 1:CD003261. [QxMD MEDLINE Link].
  23. George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. 2003 Jun. 53(491):480-7. [QxMD MEDLINE Link]. [Full Text].
  24. Brown J, Shriner DL, Schwartz RA, Janniger CK. Impetigo: an update. Int J Dermatol. 2003 Apr. 42(4):251-5. [QxMD MEDLINE Link].
  25. Parks T, Smeesters PR, Steer AC. Streptococcal skin infection and rheumatic heart disease. Curr Opin Infect Dis. 2012 Apr. 25(2):145-53. [QxMD MEDLINE Link].
  26. Mancini AJ. Bacterial skin infections in children: the common and the not so common. Pediatr Ann. 2000 Jan. 29(1):26-35. [QxMD MEDLINE Link].
  27. American Academy of Pediatrics. Group A Streptococcal infections. Pickering LK, ed. Red Book: 2012 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, Ill: American Academy of Pediatrics; 2015. 732-744.
  28. Ludlam H, Cookson B. Scrum kidney: epidemic pyoderma caused by a nephritogenic Streptococcus pyogenes in a rugby team. Lancet. 1986 Aug 9. 2(8502):331-3. [QxMD MEDLINE Link].
  29. Belgemen T, Suskan E, Dogu F, Ikinciogullari A. Selective immunoglobulin M deficiency presenting with recurrent impetigo: a case report and review of the literature. Int Arch Allergy Immunol. 2009. 149(3):283-8. [QxMD MEDLINE Link].
  30. Sarabi K, Khachemoune A. Tinea capitis: a review. Dermatol Nurs. 2007 Dec. 19(6):525-9; quiz 530. [QxMD MEDLINE Link].
  31. Popovich D, McAlhany A. Accurately diagnosing commonly misdiagnosed circular rashes. Dermatol Nurs. 2008 Aug. 20(4):294-300. [QxMD MEDLINE Link].
  32. Gorani A, Oriani A, Cambiaghi S. Seborrheic dermatitis-like tinea faciei. Pediatr Dermatol. 2005 May-Jun. 22(3):243-4. [QxMD MEDLINE Link].
  33. Hayakawa K, Hirahara K, Fukuda T, Okazaki M, Shiohara T. Risk factors for severe impetiginized atopic dermatitis in Japan and assessment of its microbiological features. Clin Exp Dermatol. 2009 Jul. 34(5):e63-5. [QxMD MEDLINE Link].
  34. Rashid R, Hymes S. Folliculitis, follicular mucinosis, and papular mucinosis as a presentation of chronic myelomonocytic leukemia. Dermatol Online J. 2009 May 15. 15(5):16. [QxMD MEDLINE Link].
  35. Gorwitz RJ. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and update. Pediatr Infect Dis J. 2008 Oct. 27(10):925-6. [QxMD MEDLINE Link].
  36. [Guideline] Rush, J and Dinulos JG. Childhood skin and soft tissue infections: new discoveries and guidelines regarding the management of bacterial soft tissue infections, molluscum contagiousum, and warts. Current Opinion in Pediatrics. April 2016. 28(2):250-257.
  37. [Guideline] Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014 Jul 15. 59 (2):147-59. [QxMD MEDLINE Link].
  38. American Academy of Pediatrics. Staphylococcal infections. Pickering LK, ed. Red Book: 2012 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015. 715-732.
  39. Scheinfeld N. A Primer In Topical Antibiotics For The Skin And Eyes. J Drugs Dermatol. 2008. 7(4):409-415.
  40. Wilkinson RD, Carey WD. Topical mupirocin versus topical neosporin in the treatment of cutaneous infections. Int J Dermatol. 1988 Sep. 27(7):514-5. [QxMD MEDLINE Link].
  41. Bass JW, Chan DS, Creamer KM, et al. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Pediatr Infect Dis J. 1997 Jul. 16(7):708-10. [QxMD MEDLINE Link].
  42. Silverberg N, Block S. Uncomplicated skin and skin structure infections in children: diagnosis and current treatment options in the United States. Clin Pediatr (Phila). 2008 Apr. 47(3):211-9. [QxMD MEDLINE Link].
  43. Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008 May. 158(5):1077-82. [QxMD MEDLINE Link].
  44. Jacobs MR. Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children. Future Microbiol. 2007 Dec. 2(6):591-600. [QxMD MEDLINE Link].
  45. Jones RS. Expert advice on erasing the MRSA threat. Pract Dermatol. 2005. 34-7.
  46. Drucker CR. Update on topical antibiotics in dermatology. Dermatol Ther. 2012 Jan-Feb. 25(1):6-11. [QxMD MEDLINE Link].
  47. Woodford N, Afzal-Shah M, Warner M, Livermore DM. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J Antimicrob Chemother. 2008 Oct. 62(4):766-8. [QxMD MEDLINE Link].
  48. Boyd B, Castañar J. Retapamulin. Drugs Future. 2006. 31:107.
  49. Oranje AP, Chosidow O, Sacchidanand S, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology. 2007. 215(4):331-40. [QxMD MEDLINE Link].
  50. Drug and Therapeutics Bulletin. Retapamulin for impetigo and other infections. Drug Ther Bull. 2008 Oct. 46(10):76-9. [QxMD MEDLINE Link].
  51. Denton M, O'Connell B, Bernard P, Jarlier V, Williams Z, Henriksen AS. The EPISA study: antimicrobial susceptibility of Staphylococcus aureus causing primary or secondary skin and soft tissue infections in the community in France, the UK and Ireland. J Antimicrob Chemother. 2008 Mar. 61(3):586-8. [QxMD MEDLINE Link].
  52. O'Neill AJ, Larsen AR, Skov R, Henriksen AS, Chopra I. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol. 2007 May. 45(5):1505-10. [QxMD MEDLINE Link]. [Full Text].
  53. Laurent F, Tristan A, Croze M, et al. Presence of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus in France. J Antimicrob Chemother. 2009 Feb. 63(2):420-1; author reply 421. [QxMD MEDLINE Link].
  54. Alsterholm M, Flytström I, Bergbrant IM, Faergemann J. Fusidic acid-resistant Staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis. Acta Derm Venereol. 2010. 90(1):52-7. [QxMD MEDLINE Link].
  55. Gelmetti C. Local antibiotics in dermatology. Dermatol Ther. 2008 May-Jun. 21(3):187-95. [QxMD MEDLINE Link].
  56. Langner A, Chu A, Goulden V, Ambroziak M. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. Br J Dermatol. 2008 Jan. 158(1):122-9. [QxMD MEDLINE Link].
  57. Capizzi R, Landi F, Milani M, Amerio P. Skin tolerability and efficacy of combination therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with benzoyl peroxide cream and adapalene gel in common acne. A randomized, investigator-masked, controlled trial. Br J Dermatol. 2004 Aug. 151(2):481-4. [QxMD MEDLINE Link].
  58. Albareda, N, Rosenberg, N., Roth, S, et al. Ozenoxacin, a Novel, Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients with Impetigo: Phase III Clinical Trials Pooled Analysis Results. SKIN The Journal of Cutaneous Medicine. 2017. 1(3.1):s102. [Full Text].
  59. Gropper S, Albareda N, Chelius K, Kruger D, Mitha I, Vahed Y, et al. Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial. Future Microbiol. 2014. 9 (9):1013-23. [QxMD MEDLINE Link].
  60. Chamny S, Miron D, Lumelsky N, Shalev H, Gazal E, Keynan R, et al. Topical Minocycline Foam for the Treatment of Impetigo in Children: Results of a Randomized, Double-Blind, Phase 2 Study. J Drugs Dermatol. 2016 Oct 1. 15 (10):1238-1243. [QxMD MEDLINE Link].
  61. Groner A, Laing-Grayman D, Silverberg NB. Outpatient pediatric community-acquired methicillin-resistant Staphylococcus aureus: a polymorphous clinical disease. Cutis. 2008 Feb. 81(2):115-22. [QxMD MEDLINE Link].
  62. Bernard P. Management of common bacterial infections of the skin. Curr Opin Infect Dis. 2008 Apr. 21(2):122-8. [QxMD MEDLINE Link].
  63. Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L, et al. Mass Drug Administration for Scabies Control in a Population with Endemic Disease. N Engl J Med. 2015 Dec 10. 373 (24):2305-13. [QxMD MEDLINE Link].
  64. Garcia J. Mass Treatment With Ivermectin Decreases Scabies Prevalence. Medscape Medical News. Available at https://www.medscape.com/viewarticle/856375. December 22, 2015; Accessed: April 1, 2016.
  65. Yang LP, Keam SJ. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs. 2008. 68(6):855-73. [QxMD MEDLINE Link].
  66. Rist T, Parish LC, Capin LR, Sulica V, Bushnell WD, Cupo MA. A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. Clin Exp Dermatol. 2002 Jan. 27(1):14-20. [QxMD MEDLINE Link].

Author

Coauthor(s)

Sahithi Talasila, BS MD Candidate, Sidney Kimmel Medical College of Thomas Jefferson University

Sahithi Talasila, BS is a member of the following medical societies: American Medical Student Association/Foundation

Disclosure: Nothing to disclose.

Chief Editor

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.

Additional Contributors

Lisa S Lewis, MD Attending Physician, Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center

Lisa S Lewis, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Acknowledgements

Sadegh Amini, MD Senior Clinical Research Fellow, Skin Research Group, Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami

Sadegh Amini, MD is a member of the following medical societies: American Society for Dermatologic Surgery, International Society for Dermatologic Surgery, and International Society of Dermatology

Disclosure: Nothing to disclose.

Anne E Burdick, MD, MPH Professor of Dermatology, Director of Leprosy Program, Associate Dean for TeleHealth and Clinical Outreach, University of Miami Miller School of Medicine

Anne E Burdick, MD, MPH is a member of the following medical societies: Women's Dermatologic Society

Disclosure: Nothing to disclose.

Ivan D Camacho, MD, Assistant Professor of Clinical Dermatology, Department of Dermatology and Cutaneous Surgery, University of Miami, Leonard M Miller School of Medicine; Medical Director of Dermatology Clinic, Jackson Memorial

Ivan D Camacho, MD is a member of American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Florida Medical Association, International Society of Dermatology, and the Women's Dermatologic Society.

Disclosure: Nothing to disclose.

Burke A Cunha, MD Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Joseph Domachowske, MD Professor of Pediatrics, Microbiology and Immunology, Department of Pediatrics, Division of Infectious Diseases, State University of New York Upstate Medical University

Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Pamela L Dyne, MD Professor of Clinical Medicine/Emergency Medicine, David Geffen School of Medicine at UCLA; Attending Physician, Department of Emergency Medicine, Olive View-UCLA Medical Center

Pamela L Dyne, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Dirk M Elston, MD Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Glenn J Fennelly, MD, MPH Director, Division of Pediatric Infectious Diseases, Jacobi Medical Center; Associate Professor, Department of Pediatrics, Albert Einstein College of Medicine

Glenn J Fennelly, MD, MPH is a member of the following medical societies: Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Allan D Friedman, MD, MPH (Retired) Chairman, Division of General Pediatrics, VCUH Health System; Professor of Pediatrics, Virginia Commonwealth University School of Medicine

Allan D Friedman, MD, MPH is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Eric M Kardon, MD, FACEP Attending Emergency Physician, Georgia Emergency Medicine Specialists; Physician, Division of Emergency Medicine, Athens Regional Medical Center

Eric M Kardon, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

Paul Krusinski, MD Director of Dermatology, Fletcher Allen Health Care; Professor, Department of Internal Medicine, University of Vermont College of Medicine

Paul Krusinski, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Andrew C Miller, MD Fellow, Department of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center; Attending Physician, Department of Emergency Medicine, University of Pittsburgh Medical Center

Andrew C Miller, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

James J Nordlund, MD Professor Emeritus, Department of Dermatology, University of Cincinnati College of Medicine

James J Nordlund, MD is a member of the following medical societies: American Academy of Dermatology, Sigma Xi, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Rashid M Rashid, MD, PhD Resident Physician, Department of Dermatology, University of Texas, Houston, MD Anderson Cancer Center, and Morzak Research Initiative

Rashid M Rashid, MD, PhD is a member of the following medical societies: American Academy of Dermatology, Council for Nail Disorders, Houston Dermatological Society, Texas Dermatological Society, and Texas Medical Association

Disclosure: Nothing to disclose.

John Ratz, MD, MBA Staff Dermatologist, Mohs Surgeon, Center for Dermatology and Skin Surgery, Inc

John Ratz, MD, MBA is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Micrographic Surgery and Cutaneous Oncology, American College of Physicians, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, International Society for Dermatologic Surgery, and Southern Medical Association

Disclosure: Nothing to disclose.

Gregory William Rutecki, MD Associate Professor, Program Director, Department of Internal Medicine, Feinberg School of Medicine, Northwestern University

Gregory William Rutecki, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Society of Nephrology, National Kidney Foundation, and Society of General Internal Medicine

Disclosure: Nothing to disclose.

Mark A Silverberg, MD, FACEP, MMB Assistant Professor, Assistant Residency Director, Department of Emergency Medicine, State University of New York Downstate College of Medicine; Consulting Staff, Department of Emergency Medicine, Staten Island University Hospital, Kings County Hospital, University Hospital, State University of New York Downstate at Brooklyn

Mark A Silverberg, MD, FACEP, MMB is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Council of Emergency Medicine Residency Directors, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Daniel B Ward Jr, MD Clinical Assistant Professor, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina

Daniel B Ward Jr, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, and South Carolina Medical Association

Disclosure: Nothing to disclose.

Eric L Weiss, MD, DTM&H Director of Stanford Travel Medicine, Medical Director of Stanford Lifeflight, Assistant Professor, Departments of Emergency Medicine and Infectious Diseases, Stanford University School of Medicine

Eric L Weiss, MD, DTM&H is a member of the following medical societies: American College of Emergency Physicians, American College of Occupational and Environmental Medicine, American Medical Association, American Society of Tropical Medicine and Hygiene, Physicians for Social Responsibility, Southeastern Surgical Congress, Southern Association for Oncology, Southern Clinical Neurological Society, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Michael J Wells, MD Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, Medscape Reference

Disclosure: Nothing to disclose.